Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653271 · ClinicalTrials.gov registry record · Phase 1
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
A Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, sponsored by Acepodia Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 13
- Study locations
NCT05653271: Recruiting Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, sponsored by Acepodia Biotech.
NCT05653271 is a Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Acepodia Biotech. The registered enrollment target is 42 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (75% lower). The trial reports 13 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05653271, a Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Acepodia Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 13
- Study locations
Study Summary
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG ACE1831
Study Locations (13)
Other
- Queen Mary Hospital - Hong Kong
- Kaohsiung Chang-Gung Memorial Hospital - Kaohsiung City
- Ministry of Health and Welfare Shuang-Ho Hospital - New Taipei City
- Tamsui MacKay Memorial Hospital - New Taipei City
- Taichung Veterans General Hospital - Taichung
- National Cheng Kung University Hospital - Tainan
- National Taiwan University Hospital - Taipei
- Linkou Chang-Gung Memorial Hospital - Taoyuan
Florida
- AdventHealth Orlando - Orlando
Georgia
- Emory University - Atlanta
Indiana
- Indiana University Simon Comprehensive Cancer Center - Indianapolis
Kentucky
- Norton Cancer Institute - Louisville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-01-21 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT05653271 shows while recruiting
NCT05653271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (75% lower).
The record links to 8 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT05653271 lists 13 locations in 6 states (Other, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT05653271 about?
NCT05653271 is a clinical study titled "ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies". ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety an...
What is the current status of trial NCT05653271?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-01-21. Estimated completion is 2027-09.
What conditions does trial NCT05653271 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, High Grade B-Cell Lymphoma.
What interventions are being tested in trial NCT05653271?
The interventions under investigation include: Obinutuzumab (DRUG), Cyclophosphamide (DRUG), Fludarabine (DRUG), ACE1831 (DRUG).
Who is sponsoring clinical trial NCT05653271?
This trial is sponsored by Acepodia Biotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653271 being conducted?
This trial has 13 study locations across Florida, Georgia, Indiana, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05653271's enrollment target sits among peer trials
42 62nd of 106 higher than 43 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI